PolyPid Raises $16.2M in Private Placement for SHIELD II Trial

TL;DR

**PolyPid just raised $16.2M, with potential for $17.9M more, to fund its crucial D-PLEX 100 trial.**

AI Summary

PolyPid Ltd. secured $16.2 million in gross proceeds from a private placement financing on January 4, 2024, by selling 3,371,312 ordinary shares at $4.81 per share to U.S. life sciences investors and existing shareholders. This deal also includes warrants to purchase an additional 3,371,312 shares at $5.50, potentially bringing in another $17.9 million. The company plans to use these funds to advance its SHIELD II Phase 3 clinical trial for D-PLEX 100, which is crucial for preventing surgical site infections, and for general working capital, directly impacting its ability to bring its key product to market.

Why It Matters

This financing provides PolyPid with critical capital to continue its SHIELD II Phase 3 trial for D-PLEX 100, a key drug candidate, which is essential for the company's future revenue and stock performance.

Risk Assessment

Risk Level: medium — While the financing provides capital, the company's success still heavily depends on the outcome of its SHIELD II Phase 3 trial, which carries inherent clinical trial risks.

Analyst Insight

A smart investor would view this financing as a positive step, providing necessary capital for PolyPid's critical clinical trial, but should monitor the SHIELD II trial's progress closely as its success is paramount to the company's future.

Key Numbers

• $16.2 million — gross proceeds (from the initial sale of shares and pre-funded warrants)
• 3,371,312 — ordinary shares (number of shares sold in the private placement)
• $4.81 — purchase price per share (price at which ordinary shares were sold)
• $17.9 million — additional gross proceeds (potential proceeds if all warrants are exercised)
• $5.50 — exercise price per share (price for exercising the warrants)

Key Players & Entities

• PolyPid Ltd. (company) — the registrant raising capital
• U.S. life sciences-focused investors (person) — lead investors in the private placement
• existing investors (person) — participants in the private placement
• Data Safety Monitoring Board (company) — board whose recommendation impacts warrant expiration
• D-PLEX 100 (company) — the drug candidate in the SHIELD II trial

Forward-Looking Statements

• PolyPid will successfully complete its SHIELD II Phase 3 trial. (PolyPid Ltd.) — medium confidence, target: 2025
• The warrants will be exercised, providing additional capital to PolyPid. (PolyPid Ltd.) — medium confidence, target: 2026

FAQ

Key Financial Figures

• $4.81 — value per share at a purchase price of $4.81 per share (the “ Ordinary Shares
• $5.50 — Ordinary Shares at an exercise price of $5.50 per share. The warrants expire upon the
• $16.2 million — ult in gross proceeds to the Company of $16.2 million. Exercise of the warrants in full would
• $17.9 million — s in full would result in an additional $17.9 million in gross proceeds to the Company. The C
• $60,000 — urse certain accountable expenses up to $60,000. In connection with the closing of the
• $16 Million — PolyPid Announces Private Placement for $16 Million in Gross Proceeds”. 99.2 Form

Filing Documents

• ea191200-6k_polypid.htm (6-K) — 18KB
• ea191200ex99-1_polypid.htm (EX-99.1) — 15KB
• ea191200ex99-2_polypid.htm (EX-99.2) — 240KB
• ea191200ex99-3_polypid.htm (EX-99.3) — 140KB
• ea191200ex99-4_polypid.htm (EX-99.4) — 97KB
• ea191200ex99-5_polypid.htm (EX-99.5) — 93KB
• 0001213900-24-001325.txt ( ) — 604KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: January 5, 2024 By: /s/ Dikla Czaczkes Akselbrad Name: Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR